Perioperative enfortumab vedotin + pembrolizumab tied to improved outcomes with bladder cancer
Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared with surgery ...
20 minutes ago
0
0









